TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients
Key facts
- Who runs it
- Aswan University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 60 people, planned
- Started
- 20 Oct 2025
- Expected to end
- 1 May 2027
- Type of study
- Observational, 2 groups
- Record updated
- 31 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adult patients (aged 18 years and older) clinically diagnosed with vitiligo, either newly diagnosed or not on treatment for at least 3 months before the study
Who cannot take part
- Patients who had recent major surgical procedures
- Vitiligo patients who have received treatment within 3 months prior to the study
- Any participant with associated inflammatory disease (such as infections or autoimmune disorders)
- Patients with chronic diseases including cardiac, hepatic, hematologic, or renal disorders, or malignancies
- Patients with segmental vitiligo
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study investigates the relationship between Transient Receptor Potential Melastatin 2 (TRPM2) gene polymorphism and Nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome expression in patients with vitiligo. Vitiligo is a common autoimmune depigmenting disorder characterized by melanocyte destruction associated with oxidative stress and immune dysregulation.
Read full original descriptionShow less
TRPM2 is a calcium-permeable cation channel activated by oxidative stress, while NLRP3 inflammasome activation promotes inflammation through interleukin-1β (IL-1β) and interleukin-18 (IL-18) release. This study aims to evaluate TRPM2 genetic variants, NLRP3 expression levels, and their possible correlation with disease severity measured using the Vitiligo Area Scoring Index (VASI).
The 2 groups in the trial
- Vitiligo Patients
Participants clinically diagnosed with vitiligo, recruited from the Dermatology Outpatient Clinic, Aswan University Hospital. Peripheral blood samples will be collected for TRPM2 gene and NLRP3 inflammasome analysis.
- Healthy Controls
Age- and sex-matched healthy individuals without autoimmune or inflammatory disorders, recruited as controls. Blood samples will be analyzed similarly for comparison.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- TRPM2 Gene Polymorphism in Relation to NLRP3 Inflammasome Expression in Vitiligo Patients
- Record updated
- 31 December 2025